Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo

Gene Therapy

Volumn 10, Issue 8, 2003, Pages 686-699

  Frelin, L ^a   Alheim, M ^a   Chen, A ^a   Soderholm J ^a   Rozell, B ^a   Barnfield, C ^b   Liljestrom P ^b,c   Sallberg M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

DNA vaccine; Gene gun; HCV; Hepatitis C virus; NS3

Indexed keywords

DNA VACCINE; HELICASE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; NONSTRUCTURAL 3 PROTEIN; NONSTRUCTURAL 4A PROTEIN; PROTEINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; EUKARYOTE; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION; GENE GUN; GENETIC TRANSFECTION; GENOTYPE; HEPATITIS C VIRUS; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VIVO STUDY; MOLECULAR CLONING; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; TH1 CELL; TUMOR CELL; VIRAL GENE THERAPY;

ANIMALS; BIOLISTICS; GENE THERAPY; HEPACIVIRUS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MULTIPLE MYELOMA; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; VACCINES, DNA; VIRAL NONSTRUCTURAL PROTEINS;

ANIMALIA; EUKARYOTA; HEPATITIS C VIRUS; VECTORS;

EID: 0038066406     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301933     Document Type: Article

References (53)

1. Weiner AJ et al. Evidence for immune selection of hepatitis-C virus (HCV) putative envelope glycoprotein variants - potential role in chronic HCV infections. Proc Natl Acad Sci USA 1992; 89: 3468-3472.
2. Ramratnam B et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999; 354: 1782-1785.
3. Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 1991; 88: 3392-3396.
4. Lu L et al. Evaluation of accumulation of hepatitis C virus mutations in a chronically infected chimpanzee: comparison of the core, E1, HVR1, and NS5b regions. J Virol 2001; 75: 3004-3009.
5. Diepolder HM et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997; 71: 6011-6019.
6. Diepolder HM et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 1006-1007.
7. Missale G et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the antiviral cell-mediated immune response. J Clin Invest 1996; 98: 706-714.
8. Bocher WO et al. Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. Eur J Immunol 2001; 31: 2071-2079.
9. Brinster C et al. Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA- expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology 2001; 34: 1206-1217.
10. Encke J, Zu Putlitz J, Geissler M, Wands JR. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol 1998; 161: 4917-4923.
11. Forns X et al. DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. Vaccine 1999; 17: 1992-2002.
12. Geissler M et al. Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs. Vaccine 1998; 16: 857-867.
13. Gordon EJ et al. Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations. J Infect Dis 2000; 181: 42-50.
14. Inchauspe G et al. Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization. DNA Cell Biol 1997; 16: 185-195.
15. Lazdina U et al. Humoral and CD4(+) T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein. J Gen Virol 2001; 82: 1299-1308.
16. Major ME et al. DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol 1995; 69: 5798-5805.
17. Satoi J et al. Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins. J Virol 2001; 75: 12121-12127.
18. Tokushige K et al. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs. Hepatology 1996; 24: 14-20.
19. Wolk B et al. Subcellular localization, stability, and transcleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline- regulated cell lines [In Process Citation]. J Virol 2000; 74: 2293-2304.
20. Tanji Y et al. Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. J Virol 1995; 69: 1575-1581.
21. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 1993; 67: 3835-3844.
22. Bartenschlager R, Lohmann V, Wilkinson T, Koch JO. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. J Virol 1995; 69: 7519-7528.
23. Failla C, Tomei L, De Francesco R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus non-structural proteins. J Virol 1994; 68: 3753-3760.
24. Pang PS, Jankowsky E, Planet PJ, Pyle AM. The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding. EMBO J 2002; 21: 1168-1176.
25. Zhang ZX et al. Characterization of a monoclonal antibody and its single-chain antibody fragment recognizing the nucleoside triphosphatase/helicase domain of the hepatitis C virus nonstructural 3 protein. Clin Diagn Lab Immunol 2000; 7: 58-63.
26. Ingallinella P et al. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry 1998; 37: 8906-8914.
27. Steinkuhler C et al. Activity of purified hepatitis C virus protease NS3 on peptide substrates. J Virol 1996; 70: 6694-6700.
28. Sallberg M et al. Immunogenicity and antigenicity of the ATPase/helicase domain of the hepatitis C virus non-structural 3 protein. J Gen Virol 1996; 77: 2721-2728.
29. Zhang ZX et al. Immune responses to the hepatitis C virus NS4A protein are profoundly influenced by the combination of the viral genotype and the host major histocompatibility complex. J Gen Virol 1997; 78: 2735-2746.
30. Schirmbeck R, Reimann J. Modulation of gene-gun-mediated Th2 immunity to hepatitis B surface antigen by bacterial CpG motifs or IL-12. Intervirology 2001; 44: 115-123.
31. Iroegbu J et al. Variability and immunogenicity of human immunodeficiency virus type 1 p24 gene quasispecies. Clin Diagn Lab Immunol 2000; 7: 377-383.
32. Dal Porto J et al. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci USA 1993; 90: 6671-6675.
33. Ljunggren HG et al. Empty MHC class I molecules come out in the cold. Nature 1990; 346: 476-480.
34. Stuber G et al. Assessment of major histocompatibility complex class I interaction with Epstein-Barr virus and human immunodeficiency virus peptides by elevation of membrane H-2 and HLA in peptide loading-deficient cells. Eur J Immunol 1992; 22: 2697-2703.
35. Roy MJ et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000; 19: 764-778.
36. Bartenschlager R et al. Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase. J Virol 1995; 69: 198-205.
37. Kim JL et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996; 87: 343-355.
38. Hartmann G et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000; 164: 1617-1624.
39. Pertmer TM, Roberts TR, Haynes JR. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol 1996; 70: 6119-6125.
40. Tuting T et al. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Ther 1999; 6: 629-636.
41. Garcia-Navarro R et al. Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12. J Virol 2001; 75: 9068-9076.
42. Rollier C et al. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology 1999; 116: 658-665.
43. Sallberg M et al. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum Gene Ther 1998; 9: 1719-1729.
44. Mehta SH et al. Protection against persistence of hepatitis C. Lancet 2002; 359: 1478-1483.
45. Leroux-Roels G et al. Lymphoproliferative responses to hepatitis C virus core, E1, E2, and NS3 in patients with chronic hepatitis C infection treated with interferon alfa. Hepatology 1996; 23: 8-16.
46. Cramp ME et al. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346-355.
47. Zhang ZX et al. Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy. J Infect Dis 1997; 175: 1294-1301.
48. Sallberg M et al. Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett 1991; 30: 59-68.
49. Jin L, Peterson DL. Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA helicase. Arch Biochem Biophys 1995; 323: 47-53.
50. Smerdou C, Liljestrom P. Non-viral amplification systems for gene transfer: vectors based on alphaviruses. Curr Opin Mol Ther 1999; 1: 244-251.
51. Smerdou C, Liljestrom P. Two-helper RNA system for production of recombinant Semliki forest virus particles. J Virol 1999; 73: 1092-1098.
52. Fleeton MN, Liljestrom P, Sheahan BJ, Atkins GJ. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based. DNA vaccines or an inactivated whole particle vaccine. J Gen Virol 2000; 81: 749-758.
53. Davis HL et al. Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. Human Gene Therapy 1993; 4: 733-740.